Oncologix (OCLG) Plans Expansion; Letter of Intent (LOI) Executed with Medical Product Company


Follow this company

Companies Mentioned

PK:OCLG
07/24/2014 [ACCESSWIRE]

ALEXANDRIA, LA / ACCESSWIRE / July 24, 2014 / Oncologix Tech Inc. (OTCPINK: OCLG), a fully reporting, diversified medical holding company with operating businesses units in medical device, healthcare services and medical products and technologies, has executed a Letter of Intent (LOI) to acquire a speciality medical products company.

"This acquisition would be our first step in growing our Medical Products Division and would establish a national footprint of product distribution and brings numerous strategic advantages that will support our three primary distribution strategies including licensed Medicare businesses, wholesale/commercial distribution, and Government agencies" said Harold Halman, President/COO.

Mr. Halman added "our Division’s strategy is to create vertical approaches of market penetration to both the patients at home and the institutional healthcare industry with a full line of integrated solutions. Our continued acquisition/expansion strategy is to acquire company’s already positioned with strong product brands, market reach and identified with strong distribution centers located within large demographic, MSA areas."

About Oncologix Tech

Oncologix is a diversified medical holding company that operates and manufactures Class II medical device products, delivers Personal Healthcare Services, and provides sales and distribution of medical products and technologies. For its clients, Oncologix provides FDA approved medical devices, state licensed healthcare services, and medical products and technologies. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company’s corporate mission is to be the best small cap medical device and healthcare services holding company in North America.

This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Company's expectations, among other things, are dependent upon economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, its ability to operate its subsidiary companies effectively, need for and availability of more capital as well as other uncontrollable or unknown factors which are more fully disclosed in the Company's filings with the Securities and Exchange Commission.

 

Contact Information

Wayne Erwin, Chairman and CEO

wayne.erwin@yahoo.com

(318) 451-9543

 

INVESTOR RELATIONS

Synergy: (888) 259- 9173

 

 

SOURCE: Oncologix Tech Inc

COMMENTS

Leave a comment...
 * 

Your Name
 *